Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer

Drug resistance is an obstacle to the effective treatment of ovarian cancer. We and others have shown that the insulin-like growth factor (IGF) signaling pathway is a novel potential target to overcome drug resistance. The purpose of this study was to validate IGF2 as a potential therapeutic target in drug resistant ovarian cancer and to determine the efficacy of targeting IGF2 in vivo. An analysis of The Cancer Genome Atlas (TCGA) data in the serous ovarian cancer cohort showed that high IGF2 mRNA expression is significantly associated with shortened interval to disease progression and death, clinical indicators of drug resistance. In a genetically diverse panel of ovarian cancer cell lines, the IGF2 mRNA levels measured in cell lines resistant to various microtubule-stabilizing agents including Taxol were found to be significantly elevated compared to the drug sensitive cell lines. The effect of IGF2 knockdown on Taxol resistance was investigated in vitro and in vivo. Transient IGF2 knockdown significantly sensitized drug resistant cells to Taxol treatment. A Taxol-resistant ovarian cancer xenograft model, developed from HEY-T30 cells, exhibited extreme drug resistance, wherein the maximal tolerated dose of Taxol did not delay tumor growth in mice. Blocking the IGF1R (a transmembrane receptor that transmits signals from IGF1 and IGF2) using a monoclonal antibody did not alter the response to Taxol. However, stable IGF2 knockdown using short-hairpin RNA in HEY-T30 effectively restored Taxol sensitivity. These findings validate IGF2 as a potential therapeutic target in drug resistant ovarian cancer and show that directly targeting IGF2 may be a preferable strategy compared with targeting IGF1R alone.

[1]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[2]  K. Becker,et al.  Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin , 2011, Journal of ovarian research.

[3]  S. Horwitz,et al.  Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. , 2001, Molecular cancer therapeutics.

[4]  Gloria S. Huang,et al.  Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice , 2006, Clinical Cancer Research.

[5]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[6]  N. Barzilai,et al.  Impaired IGF1R signaling in cells expressing longevity‐associated human IGF1R alleles , 2011, Aging cell.

[7]  Abraham Hochberg,et al.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences , 2010, Journal of Translational Medicine.

[8]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[9]  Adrian V. Lee,et al.  Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells , 1994, Molecular and Cellular Endocrinology.

[10]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[11]  A. Yasmeen,et al.  Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer , 2010, Journal of oncology.

[12]  M. Gottesman,et al.  Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein , 2012, PloS one.

[13]  D. Steiner,et al.  Post-translational Processing of the Insulin-like Growth Factor-2 Precursor , 1998, The Journal of Biological Chemistry.

[14]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[15]  P. Lollini,et al.  Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling , 2011, Oncogene.

[16]  D. Leroith,et al.  Minireview: IGF, Insulin, and Cancer. , 2011, Endocrinology.

[17]  R C Young,et al.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. , 1984, Seminars in oncology.

[18]  H. Nagase,et al.  Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma , 2010, European Archives of Oto-Rhino-Laryngology.

[19]  M. Ratajczak,et al.  Parental imprinting regulates insulin-like growth factor signaling: a Rosetta Stone for understanding the biology of pluripotent stem cells, aging and cancerogenesis , 2013, Leukemia.

[20]  M. Pollak,et al.  Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[21]  S. Horwitz,et al.  MUTATIONS IN BETATUBULIN MAP TO DOMAINS INVOLVED IN REGULATION OF MICROTUBULE STABILITY IN EPOTHILONE-RESISTANT CELL LINES , 2001 .

[22]  Z. Duan,et al.  Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. , 2004, Molecular cancer therapeutics.

[23]  S. Horwitz,et al.  Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells. , 2010, Gynecologic oncology.

[24]  J. Lautenberger,et al.  Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells , 1982, Nature.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  S. Horwitz,et al.  Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.

[27]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[28]  Maria Ballester,et al.  Real-time quantitative PCR-based system for determining transgene copy number in transgenic animals. , 2004, BioTechniques.

[29]  Carsten Denkert,et al.  Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. , 2009, Cancer research.

[30]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[31]  B. Sikic,et al.  Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. , 2009, Leukemia research.

[32]  R. Horobin,et al.  Identifying apoptotic cells with the 3-hydroxyflavone derivative F2N12S, a ratiometric fluorescent small molecule probe selective for plasma membranes: a possible general mechanism for selective uptake into apoptotic cells , 2011, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[33]  Tiffany M Hebert,et al.  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer , 2010, Clinical Cancer Research.

[34]  R. Baxter,et al.  Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer , 2012, The Journal of Biological Chemistry.

[35]  Elizabeth J. Robertson,et al.  Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.